155 related articles for article (PubMed ID: 21586140)
1. Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group.
Yoon HH; Catalano PJ; Murphy KM; Skaar TC; Philips S; Powell M; Montgomery EA; Hafez MJ; Offer SM; Liu G; Meltzer SJ; Wu X; Forastiere AA; Benson AB; Kleinberg LR; Gibson MK
BMC Cancer; 2011 May; 11():176. PubMed ID: 21586140
[TBL] [Abstract][Full Text] [Related]
2. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group.
Yoon HH; Catalano P; Gibson MK; Skaar TC; Philips S; Montgomery EA; Hafez MJ; Powell M; Liu G; Forastiere AA; Benson AB; Kleinberg LR; Murphy KM
Cancer Chemother Pharmacol; 2011 Oct; 68(4):863-70. PubMed ID: 21286719
[TBL] [Abstract][Full Text] [Related]
3. ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Vallböhmer D; Alakus H; Kütting F; Lurje G; Bollschweiler E; Wienand-Dorweiler A; Drebber U; Hölscher AH; Metzger R
J Gastrointest Surg; 2009 Aug; 13(8):1411-21. PubMed ID: 19421825
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk.
Tse D; Zhai R; Zhou W; Heist RS; Asomaning K; Su L; Lynch TJ; Wain JC; Christiani DC; Liu G
Cancer Causes Control; 2008 Dec; 19(10):1077-83. PubMed ID: 18478337
[TBL] [Abstract][Full Text] [Related]
5. DNA repair XRCC1 Arg399Gln polymorphism is associated with the risk of development of end-stage renal disease.
Trabulus S; Guven GS; Altiparmak MR; Batar B; Tun O; Yalin AS; Tunckale A; Guven M
Mol Biol Rep; 2012 Jun; 39(6):6995-7001. PubMed ID: 22302399
[TBL] [Abstract][Full Text] [Related]
6. Association between XRCC1 and ERCC1 single-nucleotide polymorphisms and the efficacy of concurrent radiochemotherapy in patients with esophageal squamous cell carcinoma.
Huang X; Liu C; Cui Y; Zhang H; Liu Y; Zhou X; Luo J
Oncol Lett; 2017 Feb; 13(2):704-714. PubMed ID: 28356949
[TBL] [Abstract][Full Text] [Related]
7. Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma.
Yin Z; Zhou B; He Q; Li M; Guan P; Li X; Cui Z; Xue X; Su M; Ma R; Bai W; Xia S; Jiang Y; Xu S; Lv Y; Li X
BMC Cancer; 2009 Dec; 9():439. PubMed ID: 20003463
[TBL] [Abstract][Full Text] [Related]
8. XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk.
Liu G; Zhou W; Yeap BY; Su L; Wain JC; Poneros JM; Nishioka NS; Lynch TJ; Christiani DC
Carcinogenesis; 2007 Jun; 28(6):1254-8. PubMed ID: 17264068
[TBL] [Abstract][Full Text] [Related]
9. Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India.
Sreeja L; Syamala VS; Syamala V; Hariharan S; Raveendran PB; Vijayalekshmi RV; Madhavan J; Ankathil R
J Cancer Res Clin Oncol; 2008 Jun; 134(6):645-52. PubMed ID: 17952468
[TBL] [Abstract][Full Text] [Related]
10. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.
Wu X; Gu J; Wu TT; Swisher SG; Liao Z; Correa AM; Liu J; Etzel CJ; Amos CI; Huang M; Chiang SS; Milas L; Hittelman WN; Ajani JA
J Clin Oncol; 2006 Aug; 24(23):3789-98. PubMed ID: 16785472
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis.
Metzger R; Warnecke-Eberz U; Alakus H; Kütting F; Brabender J; Vallböhmer D; Grimminger PP; Mönig SP; Drebber U; Hölscher AH; Bollschweiler E
J Gastrointest Surg; 2012 Jan; 16(1):26-34; discussion 34. PubMed ID: 21956434
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma.
Casson AG; Zheng Z; Evans SC; Veugelers PJ; Porter GA; Guernsey DL
Carcinogenesis; 2005 Sep; 26(9):1536-41. PubMed ID: 15878910
[TBL] [Abstract][Full Text] [Related]
13. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
Rumiato E; Cavallin F; Boldrin E; Cagol M; Alfieri R; Basso D; Castoro C; Ancona E; Amadori A; Ruol A; Saggioro D
Pharmacogenet Genomics; 2013 Nov; 23(11):597-604. PubMed ID: 23962907
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in XPC, XPD, XRCC1, and XRCC3 DNA repair genes and lung cancer risk in a population of northern Spain.
López-Cima MF; González-Arriaga P; García-Castro L; Pascual T; Marrón MG; Puente XS; Tardón A
BMC Cancer; 2007 Aug; 7():162. PubMed ID: 17705814
[TBL] [Abstract][Full Text] [Related]
15. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
[TBL] [Abstract][Full Text] [Related]
16. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
[TBL] [Abstract][Full Text] [Related]
17. Impact of DNA repair genes polymorphism (XPD and XRCC1) on the risk of breast cancer in Egyptian female patients.
Hussien YM; Gharib AF; Awad HA; Karam RA; Elsawy WH
Mol Biol Rep; 2012 Feb; 39(2):1895-901. PubMed ID: 21643959
[TBL] [Abstract][Full Text] [Related]
18. Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.
Han B; Guo Z; Ma Y; Kang S; Wang Y; Wei Q; Wu X
Int J Clin Exp Pathol; 2015; 8(4):4113-9. PubMed ID: 26097600
[TBL] [Abstract][Full Text] [Related]
19. Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis.
Cui Z; Yin Z; Li X; Wu W; Guan P; Zhou B
BMC Cancer; 2012 Feb; 12():71. PubMed ID: 22339849
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes.
Bradbury PA; Kulke MH; Heist RS; Zhou W; Ma C; Xu W; Marshall AL; Zhai R; Hooshmand SM; Asomaning K; Su L; Shepherd FA; Lynch TJ; Wain JC; Christiani DC; Liu G
Pharmacogenet Genomics; 2009 Aug; 19(8):613-25. PubMed ID: 19620936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
